Cardiovascular diseases are the leading cause of death globally and are associated with
increasing financial expenditure. With the availability of next-generation sequencing …

Atherosclerosis is the main underlying pathology for many cardiovascular diseases (CVDs),
which are the leading cause of death globally and represent a serious health crisis …

Background: The adult mammalian heart has limited regenerative capacity, mostly
attributable to postnatal cardiomyocyte cell cycle arrest. In the last 2 decades, numerous …

The field of gene therapy has evolved over the past two decades after the first introduction of
nucleic acid drugs, such as plasmid DNA (pDNA). With the development of in vitro …

Messenger RNA (mRNA) holds great potential in develo** immunotherapy, protein
replacement, and genome editing. In general, mRNA does not have the risk of being …

Messenger RNA (mRNA) has become a promising class of drugs for diverse therapeutic
applications in the past few years. A series of clinical trials are ongoing or will be initiated in …

Abstract Lipid Nanoparticles (LNPs) are a promising drug delivery vehicle for clinical siRNA
delivery. Modified mRNA (modRNA) has recently gained great attention as a therapeutic …

Background: Sphingolipids have recently emerged as a biomarker of recurrence and
mortality after myocardial infarction (MI). The increased ceramide levels in mammalian heart …

Myocardial infarction (MI) and heart failure (HF) are the leading causes of death in the
United States and in most other industrialized nations. MI leads to a massive loss of …

Many conditions can benefit from RNA-based therapies, namely, those targeting internal
ribosome entry sites (IRESs) and their regulatory proteins, the IRES trans-acting factors …